Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1α protein accumulation by NSC 644221

Clinical Cancer Research

Volumn 13, Issue 3, 2007, Pages 1010-1018

  Creighton Gutteridge, Mark ^a   Cardellina II, John H ^a   Stephen, Andrew G ^b   Rapisarda, Annamaria ^b   Uranchimeg, Badarch ^b   Hite, Karen ^b   Denny, William A ^c   Shoemaker, Robert H ^a   Melillo, Giovanni ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; DNA TOPOISOMERASE (ATP HYDROLYSING); HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; LUCIFERASE; MESSENGER RNA; METHIONINE; NSC 644221; PROTEASOME INHIBITOR; PROTEIN INHIBITOR; PROTEIN P21; SMALL INTERFERING RNA; SULFUR 35; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL SPECIFICITY; CELL TYPE; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; DRUG SCREENING; GENE SILENCING; HUMAN; HUMAN CELL; HYPOXIA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION;

AMIDES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUCIFERASES; MODELS, CHEMICAL; NEOPLASMS; POLYCYCLIC COMPOUNDS; RNA, MESSENGER; RNA, SMALL INTERFERING; TEMPERATURE; TIME FACTORS; TRANSFECTION;

EID: 33847421328     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2301     Document Type: Article

References (27)

1. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408-16.
2. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
3. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
4. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004;5:343-54.
5. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 2002;31:27975-81.
6. Mabjeesh NJ, Post DE, Willard MT, et al. Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteosome pathway in prostate cancer cells. Cancer Res 2002;62:2478-82.
7. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway. J Biol Chem 2002;277:29936-44.
8. Mabjeesh NJ, Escuin D, LaVallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003;4:363-75.
9. Chun YS, Yeo EJ, Choi E, et al. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol 2001;61:947-54.
10. Rapisarda A, Uranchimeg B, Scudiero DA, et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 2002;62:4316-24.
11. Kong D, Park EJ, Stephen AG, et al. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res 2005;65:9047-55.
12. Park H. Aromatic hydrocarbon nuclear translocator as a common component for the hypoxia- and dioxin-induced gene expression. Mol Cells 1999;9:172-8.
13. Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 2004;64:1475-82.
14. Lee HH, Palmer BD, Boyd M, Baguley BC, Denny WA. Potential antitumor agents. 64. Synthesis and antitumor evaluation of dibenzo [1,4] dioxin-1-carboxamides: a new class of weakly binding DNA-intercalating agents. J Med Chem 1992;35:258-66.
15. Melillo G. HIF-1: a target for cancer, ischemia, and inflammation - too good to be true? Cell Cycle 2004;3:154-5.
16. Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. Nat Rev Drug Discov 2003;2:803-11.
17. Welsh SJ, Koh MY, Powls G, The hypoxic inducible stress response as a target for cancer drug discovery. Semin Oncol 2006;4:486-97.
18. Melillo G. Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res 2006;4:601-5.
19. Porter AC, Farr CJ. Topoisomerase II: untangling its contribution at the centromere. Chromosome Res 2004;12:569-83.
20. Sakaguchi A, Kikuchi A. Functional compatibility between isoform α and β of type II DNA topoisomerase. J Cell Sci 2004;117:1047-54.
21. Akimitsu N, Adachi N, Hirai H, et al. Enforced cytokinesis without complete nuclear division in embryonic cells depleting the activity of DNA topoisomerase IIα. Genes Cells 2003;8:393-402.
22. Grue P, Grasser A, Sehested M, et al. Essential mitotic functions of DNA topoisomerase IIα are not adopted by topoisomerase IIβ in human H69 cells. J Biol Chem 1998;273:33660-6.
23. Perrin D, van Hille B, Hill BT. Differential sensitivities of recombinant human topoisomerase IIα and β to various classes of topoisomerase II-interacting agents. Biochem Pharmacol 1998;56:503-7.
24. Ogiso Y, Tomida A, Lei S, Omura S, Tsuruo T. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res 2000;60:2429-34.
25. Kaluzova M, Kaluz S, Lerman MI, Stanbridge EJ. DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1α in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX. Mol Cell Biol 2004;24:5757-66.
26. Palmer BD, Rewcastle GW, Atwell GJ, Baguley BC, Denny WA. Potential antitumor agents. 54. Chromophore requirements for in vivo antitumor activity among the general class of linear tricyclic carboxamides. J Med Chem 1998;31:707-12.
27. Osman S, Rowlinson-Busza G, Luthra SK, et al. Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino)ethyl]acridine- 4-carboxamide and DNA-intercalating analogues Cancer Res 2001;61:2935-44.